ArticleAntimicrobial agents and chemotherapy2019
Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- The Status of Carbapenem Resistance in Cystic Fibrosis: A Systematic Review and Meta-Analysis.The Yale journal of biology and medicine · 2022Pooled it
- Article
- Loss of DNA mismatch repair genes leads to acquisition of antibiotic resistance independent of secondary mutations.PLoS genetics · 2026Article
- Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives.BMC microbiology · 2025Article
- Article
- Co-culture biofilm patterns among different Pseudomonas aeruginosa clones from cystic fibrosis patients.Biofilm · 2025Article
- OvercomingAntibiotics (Basel, Switzerland) · 2025Review
- Experimental evolution ofMicrobiology spectrum · 2025Article
- Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions.The Journal of antimicrobial chemotherapy · 2025Article
- Hypermutability bypasses genetic constraints in SCV phenotypic switching in Pseudomonas aeruginosa biofilms.NPJ biofilms and microbiomes · 2025Article
- Current Approaches in Genome Assembly of Human Fungal Pathogens.Methods in molecular biology (Clifton, N.J.) · 2025Article
- The Challenging Life of Mutators: HowMicroorganisms · 2024Article
- Molecular characterization of clinically isolatedAntimicrobial agents and chemotherapy · 2024Article
- Ecological and evolutionary mechanisms driving within-patient emergence of antimicrobial resistance.Nature reviews. Microbiology · 2024Review
- Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam inAntimicrobial agents and chemotherapy · 2024Article
- The role of hypermutation and collateral sensitivity in antimicrobial resistance diversity ofmBio · 2024Article
- Secondary messenger signalling influences Pseudomonas aeruginosa adaptation to sinus and lung environments.The ISME journal · 2024Article
- Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.Antimicrobial agents and chemotherapy · 2023Article
- Ceftolozane/tazobactam heteroresistance in cystic fibrosis-relatedJAC-antimicrobial resistance · 2023Article
- Assessing the relative importance of bacterial resistance, persistence and hyper-mutation for antibiotic treatment failure.Proceedings. Biological sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypermutable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.